

**Gastric acid suppression therapy and its association with peritoneal-dialysis associated peritonitis in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)**

Supplemental Tables, Figures

**Supplemental Table 1.** Peritonitis organism classifications

<b>Organism</b>	<b>Type</b>	<b>Enteric</b>
<i>Acinetobacter</i> species	Gram-negative	
Anaerobic bacteria (Other)	Others	x
<i>Bacillus</i> species	Gram-positive	x
<i>Bacteroides</i> (Anaerobe)	Others	x
<i>Candida albicans</i>	Yeast	
<i>Candida</i> , Other	Yeast	
<i>Citrobacter</i> species	Gram-negative	x
Coagulase-negative staphylococci – <i>Staphylococcus epidermidis</i>	Gram-positive	
Coagulase-negative staphylococci, Others	Gram-positive	
Coagulase-negative staphylococci, Unknown	Gram-positive	
Culture negative	Culture Negative	
<i>Diphtheroids</i> ( <i>Corynebacterium</i> )	Gram-positive	
<i>E. coli</i>	Gram-negative	x
<i>Enterobacter</i> species	Gram-negative	x
<i>Enterococcus</i> ( <i>Streptococcus faecalis/faecium</i> )	Gram-positive	x
Fungi/Yeast, Others	Yeast	
Gram-negative organisms, Others	Gram-negative	x
Gram-negative organisms, Unknown	Gram-negative	x
Gram-positive organisms, Unknown	Gram-positive	
Gram-positive organisms, Others	Gram-positive	
<i>Klebsiella</i> species	Gram-negative	x
<i>Morganella</i> species	Gram-negative	x
<i>Mycobacterium</i> , Others	Other	
<i>Mycobacterium tuberculosis</i>	Other	
<i>Neisseria</i> species	Gram-negative	x
Other enterobacteria (Coliforms)	Gram-negative	x
<i>Pasteurella</i> species	Gram-negative	x
<i>Proteus</i> species	Gram-negative	x
<i>Pseudomonas aeruginosa</i>	Gram-negative	x
<i>Pseudomonas cepacia</i>	Gram-negative	x
<i>Pseudomonas stutzeri</i>	Gram-negative	x
<i>Pseudomonas</i> , Others	Gram-negative	x
<i>Pseudomonas</i> , Unknown	Gram-negative	x

<i>Serratia</i> species	Gram-negative	x
<i>Staphylococcus aureus</i> , Methicillin-resistant	Gram-positive	
<i>Staphylococcus aureus</i> , non-MRSA	Gram-positive	
<i>Staphylococcus aureus</i> , Unknown sensitivity	Gram-positive	
<i>Stenotrophomonas maltophilia</i>	Gram-negative	x
<i>Streptococcus viridians</i> group ( <i>sanguis</i> , <i>bovis</i> , <i>mitis</i> , etc.)	Gram-positive	
<i>Streptococcus</i> , Others	Gram-positive	
<i>Streptococcus</i> , Unknown	Gram Positive	

**Figures**


**Supplemental Figure 1:** Sensitivity analysis with censoring baseline non-users at treatment initiation and baseline users at treatment discontinuation.

**A. Censor at treatment discontinuation. B. Censor at treatment initiation.**

## Association between GAS and outcomes censor at medication discontinuation


Figure S1A

Hazard Ratio (95% CI)



# Association between GAS and outcomes censor at medication initiation

Figure S1B



## Abbreviations:


GAS, gastric acid suppressants; H2RA, histamine 2 receptor antagonist; PPI, proton pump inhibitor

Peritonitis: patients: n=22287, events: n=3682; 6% of patients on H2RA, 25% PPI, 69% neither. Mortality: patients: n=23487, events: n=2906; 6% of patients on H2RA, 25% PPI, 69% neither. Model 1 adjusted for patient age, sex, black race, PD vintage, PD modality; model 2 adjusted for model 1 + 12 comorbidities; model 3 adjusted for model 2 + serum albumin, 24-hour urine volume, potassium, and magnesium; model 4 adjusted for model 3 + GI comorbidities. The overall GAS was estimated from a separate model.

**Supplemental Figure 2:** Association between gastric acid suppression use and peritonitis, subgroup analysis. Cox model stratified by country, US EHR source, and phase, adjusted for patient age, sex, black race, PD vintage, PD modality, 13 comorbidities, serum albumin, 24-hour urine volume, potassium, and magnesium.

**Subgroups**

**Figure S2**



**Adjusted Hazard Ratio (95% CI)**

**Abbreviations:** GAS, gastric acid suppressants; H2RA, histamine 2 receptor antagonist; PPI, proton pump inhibitor; CAPD, continuous ambulatory peritoneal dialysis; APD, automated peritoneal dialysis.